Compare Adaptive Biotechnologies Corp (ADPT) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Sprott Uranium Miners ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Sprott Uranium Miners ETF trades at $55.4. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | URNM | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $25.45 | $83.99 |
52-Week Low | $12.30 | $44.14 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
URNM trades at $55.39, up 1.45% today, with a bullish technical signal supported by moving averages. Recent news highlights nuclear energy's role in meeting AI power demand, with government funding and international deals creating positive momentum. The ETF focuses on uranium miners, offering concentrated exposure to the nuclear supply chain.
The outlook for URNM is positive due to growing nuclear energy demand from AI data centers and government support, though risks include uranium price volatility and concentrated miner exposure. Wall Street sentiment is mixed, with some analysts favoring pure-miner funds while others caution on valuation gaps versus spot prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
